{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:00:45Z","timestamp":1794916845125,"version":"4.9.1"},"reference-count":95,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,9]],"date-time":"2027-01-09T00:00:00Z","timestamp":1799452800000},"content-version":"am","delay-in-days":373,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012802","name":"Ragon Institute of Mass General MIT and Harvard","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012802","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["CA264646"],"award-info":[{"award-number":["CA264646"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.medj.2025.100925","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T21:50:25Z","timestamp":1763502625000},"page":"100925","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Epstein-Barr-virus-specific functional antibody signatures in the context of nasopharyngeal carcinoma development"],"prefix":"10.1016","volume":"7","author":[{"given":"Vicky","family":"Roy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin P.","family":"Kellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Lun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadege","family":"Nziza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daritza","family":"Germosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riley","family":"Bonifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth M.","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly J.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitta","family":"Michels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tseng-Cheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Jen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa M.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Waterboer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandita","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan W.","family":"Newell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Streeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galit","family":"Alter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Hildesheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4687-9626","authenticated-orcid":false,"given":"Boris","family":"Julg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2025.100925_bib1","series-title":"All Cancers Factsheet","year":"2022"},{"key":"10.1016\/j.medj.2025.100925_bib2","series-title":"Nasopharynx Cancer Factsheet","author":"Observatory","year":"2022"},{"key":"10.1016\/j.medj.2025.100925_bib3","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1002\/jmv.24262","article-title":"Evaluation of a PCR\/ESI-MS platform to identify respiratory viruses from nasopharyngeal aspirates","volume":"87","author":"Lin","year":"2015","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.medj.2025.100925_bib4","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.12659\/MSM.894951","article-title":"Expression of Serum Sialic Acid, Early Antigen-IgA, and Viral Capsid Antigen-IgA in Nasopharynx Cancer Patients: The Diagnostic Implication of Combined Assays","volume":"21","author":"Sun","year":"2015","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.medj.2025.100925_bib5","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1186\/1471-2407-10-446","article-title":"Traditional Cantonese diet and nasopharyngeal carcinoma risk: a large-scale case-control study in Guangdong, China","volume":"10","author":"Jia","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.medj.2025.100925_bib6","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2016.0270","article-title":"Epstein-Barr virus infection and nasopharyngeal carcinoma","volume":"372","author":"Tsao","year":"2017","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.medj.2025.100925_bib7","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/jnci\/djs320","article-title":"An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation","volume":"104","author":"Xu","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.medj.2025.100925_bib8","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/aje\/kws479","article-title":"Quantitative association of tobacco smoking with the risk of nasopharyngeal carcinoma: a comprehensive meta-analysis of studies conducted between 1979 and 2011","volume":"178","author":"Xue","year":"2013","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.medj.2025.100925_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019100","article-title":"Fluctuations of epstein-barr virus serological antibodies and risk for nasopharyngeal carcinoma: a prospective screening study with a 20-year follow-up","volume":"6","author":"Cao","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.medj.2025.100925_bib10","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1158\/1078-0432.CCR-17-1929","article-title":"Identification of a Novel, EBV-Based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan","volume":"24","author":"Coghill","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2025.100925_bib11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/jnci\/djad012","article-title":"Recommendations for Epstein-Barr virus-based screening for nasopharyngeal cancer in high- and intermediate-risk regions","volume":"115","author":"Lam","year":"2023","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.medj.2025.100925_bib12","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/ijc.33006","article-title":"Epstein-Barr virus and human papillomavirus serum antibodies define the viral status of nasopharyngeal carcinoma in a low endemic country","volume":"147","author":"Simon","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.medj.2025.100925_bib13","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1038\/s41467-021-25402-z","article-title":"A comprehensive risk score for effective risk stratification and screening of nasopharyngeal carcinoma","volume":"12","author":"Zhou","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.medj.2025.100925_bib14","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa2301496","article-title":"Anti-Epstein-Barr Virus BNLF2b for Mass Screening for Nasopharyngeal Cancer","volume":"389","author":"Li","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2025.100925_bib15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.23.01296","article-title":"Impact of an Epstein-Barr Virus Serology-Based Screening Program on Nasopharyngeal Carcinoma Mortality: A Cluster-Randomized Controlled Trial","volume":"43","author":"Chen","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100925_bib16","doi-asserted-by":"crossref","first-page":"e00077-20","DOI":"10.1128\/JCM.00077-20","article-title":"Validation of an Epstein-Barr Virus Antibody Risk Stratification Signature for Nasopharyngeal Carcinoma by Use of Multiplex Serology","volume":"58","author":"Simon","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.medj.2025.100925_bib17","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.oraloncology.2012.10.001","article-title":"Determination of antibodies directed at EBV proteins expressed in both latent and lytic cycles in nasopharyngeal carcinoma","volume":"49","author":"Ai","year":"2013","journal-title":"Oral Oncol."},{"key":"10.1016\/j.medj.2025.100925_bib18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijporl.2018.05.032","article-title":"Increased anti- EBV VCA IgG antibody levels are associated with need for surgery in patients developing upper respiratory tract complications","volume":"111","author":"Arslan","year":"2018","journal-title":"Int. J. Pediatr. Otorhinolaryngol."},{"key":"10.1016\/j.medj.2025.100925_bib19","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.annonc.2022.04.068","article-title":"Improved risk stratification of nasopharyngeal cancer by targeted sequencing of Epstein-Barr virus DNA in post-treatment plasma","volume":"33","author":"Chan","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.medj.2025.100925_bib20","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1158\/1940-6207.CAPR-17-0035","article-title":"Multiparametric Detection of Antibodies against Different EBV Antigens to Predict Risk for Nasopharyngeal Carcinoma in a High-Risk Population of China","volume":"10","author":"Chen","year":"2017","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.medj.2025.100925_bib21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/ijc.1641","article-title":"Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum","volume":"97","author":"Cheng","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.medj.2025.100925_bib22","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1158\/1078-0432.CCR-15-2299","article-title":"High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma","volume":"22","author":"Coghill","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2025.100925_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac635","article-title":"Epstein-Barr Virus Glycoprotein Antibody Titers and Risk of Nasopharyngeal Carcinoma","volume":"9","author":"Coghill","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.medj.2025.100925_bib24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jim.2010.12.016","article-title":"A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples","volume":"366","author":"Ackerman","year":"2011","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.medj.2025.100925_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2019.07.002","article-title":"A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation","volume":"473","author":"Fischinger","year":"2019","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.medj.2025.100925_bib26","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.it.2017.02.004","article-title":"The Immunoregulatory Roles of Antibody Glycosylation","volume":"38","author":"Jennewein","year":"2017","journal-title":"Trends Immunol."},{"key":"10.1016\/j.medj.2025.100925_bib27","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jim.2019.05.006","article-title":"A versatile high-throughput assay to characterize antibody-mediated neutrophil phagocytosis","volume":"471","author":"Karsten","year":"2019","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.medj.2025.100925_bib28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.medj.2025.100925_bib29","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/imr.12503","article-title":"Systems serology for evaluation of HIV vaccine trials","volume":"275","author":"Ackerman","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.medj.2025.100925_bib30","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.immuni.2020.07.020","article-title":"Distinct Early Serological Signatures Track with SARS-CoV-2 Survival","volume":"53","author":"Atyeo","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.medj.2025.100925_bib31","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41591-021-01263-3","article-title":"Humoral signatures of protective and pathological SARS-CoV-2 infection in children","volume":"27","author":"Bartsch","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2025.100925_bib32","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3389\/fimmu.2019.00440","article-title":"Extra-Neutralizing FcR-Mediated Antibody Functions for a Universal Influenza Vaccine","volume":"10","author":"Boudreau","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.medj.2025.100925_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-40699-8","article-title":"Antibody-mediated NK cell activation as a correlate of immunity against influenza infection","volume":"14","author":"Boudreau","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.medj.2025.100925_bib34","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.cell.2015.10.027","article-title":"Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology","volume":"163","author":"Chung","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.medj.2025.100925_bib35","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abm3151","article-title":"Antibody Fc characteristics and effector functions correlate with protection from symptomatic dengue virus type 3 infection","volume":"14","author":"Dias","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.medj.2025.100925_bib36","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140925","article-title":"IgG3 collaborates with IgG1 and IgA to recruit effector function in RV144 vaccinees","volume":"5","author":"Fischinger","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.medj.2025.100925_bib37","article-title":"Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M vaccination","author":"Gorman","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.medj.2025.100925_bib38","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/infdis\/jiz364","article-title":"Survivors of Ebola Virus Disease Develop Polyfunctional Antibody Responses","volume":"221","author":"Gunn","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.medj.2025.100925_bib39","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.chom.2018.07.009","article-title":"A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus","volume":"24","author":"Gunn","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.medj.2025.100925_bib40","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.cell.2017.06.048","article-title":"Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo","volume":"170","author":"Horwitz","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.medj.2025.100925_bib41","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41577-020-0359-5","article-title":"Dissecting antibody-mediated protection against SARS-CoV-2","volume":"20","author":"Zohar","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.medj.2025.100925_bib42","doi-asserted-by":"crossref","first-page":"580","DOI":"10.3389\/fimmu.2016.00580","article-title":"Advances in Therapeutic Fc Engineering - Modulation of IgG-Associated Effector Functions and Serum Half-life","volume":"7","author":"Saxena","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.medj.2025.100925_bib43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41541-023-00628-8","article-title":"Differences in HPV-specific antibody Fc-effector functions following Gardasil(R) and Cervarix(R) vaccination","volume":"8","author":"Roy","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.medj.2025.100925_bib44","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ccell.2018.02.010","article-title":"Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies","volume":"33","author":"Arce Vargas","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.medj.2025.100925_bib45","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.3390\/cancers12103041","article-title":"Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies","volume":"12","author":"van der Horst","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.medj.2025.100925_bib46","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41568-023-00637-8","article-title":"Fc\u03b3 receptors and immunomodulatory antibodies in cancer","volume":"24","author":"Galvez-Cancino","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.medj.2025.100925_bib47","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41571-023-00827-1","article-title":"Nasopharyngeal cancer screening with an anti-BNLF2b antibody: a new arrow in the quiver?","volume":"21","author":"Lam","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100925_bib48","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1002\/ijc.35061","article-title":"Multiplex assays reveal anti-EBV antibody profile and its implication in detection and diagnosis of nasopharyngeal carcinoma","volume":"155","author":"Ma","year":"2024","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.medj.2025.100925_bib49","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1097\/MS9.0000000000000963","article-title":"EBV-IgA antibody responses in endemic and nonendemic populations with nasopharyngeal carcinoma: tumour marker prognostication study and a cross-sectional study","volume":"85","author":"Budiningsih","year":"2023","journal-title":"Ann. Med. Surg."},{"key":"10.1016\/j.medj.2025.100925_bib50","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1128\/CVI.00104-14","volume":"21","author":"Corrales","year":"2014","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.medj.2025.100925_bib51","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01528-22","article-title":"The Epstein-Barr Virus Glycoprotein BDLF2 Is Essential for Efficient Viral Spread in Stratified Epithelium","volume":"97","author":"Walston","year":"2023","journal-title":"J. Virol."},{"key":"10.1016\/j.medj.2025.100925_bib52","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.molmed.2016.09.002","article-title":"Modulating Antibody Functionality in Infectious Disease and Vaccination","volume":"22","author":"Gunn","year":"2016","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.medj.2025.100925_bib53","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/imr.12350","article-title":"Mouse and human FcR effector functions","volume":"268","author":"Bruhns","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.medj.2025.100925_bib54","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/ijc.2910120208","article-title":"Nasopharyngeal carcinoma. IV. Evolution of complement-fixing antibodies during the course of the disease","volume":"12","author":"De-Th\u00e9","year":"1973","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.medj.2025.100925_bib55","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/ijc.2910290307","article-title":"Complement-fixing antibody to Epstein-Barr virus soluble antigen in populations at high and low risk for nasopharyngeal carcinoma","volume":"29","author":"Levine","year":"1982","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.medj.2025.100925_bib56","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2003648","article-title":"CCAAT\/enhancer binding protein \u03b4 in macrophages contributes to immunosuppression and inhibits phagocytosis in nasopharyngeal carcinoma","volume":"6","author":"Hsiao","year":"2013","journal-title":"Sci. Signal."},{"key":"10.1016\/j.medj.2025.100925_bib57","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.3389\/fonc.2020.01779","article-title":"Accuracy Evaluation and Comparison of 14 Diagnostic Markers for Nasopharyngeal Carcinoma: A Meta-Analysis","volume":"10","author":"Feng","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.medj.2025.100925_bib58","article-title":"Biomarkers in Nasopharyngeal Carcinoma (NPC): Clinical relevance and prognostic potential","volume":"11","author":"Krishnan","year":"2024","journal-title":"Oral Oncol. Rep."},{"key":"10.1016\/j.medj.2025.100925_bib59","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1002\/cam4.1345","article-title":"Establishment and validation of a two-step screening scheme for improved performance of serological screening of nasopharyngeal carcinoma","volume":"7","author":"Li","year":"2018","journal-title":"Cancer Med."},{"key":"10.1016\/j.medj.2025.100925_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15092578","article-title":"Development of a Duplex Serological Multiplex Assay for the Simultaneous Detection of Epstein-Barr Virus IgA and IgG Antibodies in Nasopharyngeal Carcinoma Patients","volume":"15","author":"Schieber","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.medj.2025.100925_bib61","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1128\/JCM.43.7.3066-3073.2005","article-title":"Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia","volume":"43","author":"Stevens","year":"2005","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.medj.2025.100925_bib62","doi-asserted-by":"crossref","first-page":"e00901-20","DOI":"10.1128\/mSphere.00901-20","article-title":"Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma","volume":"5","author":"Zhu","year":"2020","journal-title":"mSphere"},{"key":"10.1016\/j.medj.2025.100925_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.106582","article-title":"Selective SARS-CoV2 BA.2 escape of antibody Fc\/Fc-receptor interactions","volume":"26","author":"Bartsch","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.medj.2025.100925_bib64","article-title":"Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy","volume":"3","author":"Herman","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.medj.2025.100925_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2022.102117","article-title":"Nasopharyngeal carcinoma patients from Norway show elevated Epstein-Barr virus IgA and IgG antibodies prior to diagnosis","volume":"77","author":"Simon","year":"2022","journal-title":"Cancer Epidemiol."},{"key":"10.1016\/j.medj.2025.100925_bib66","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/ijc.35037","article-title":"Kinetics of EBV antibody-based NPC risk scores in Taiwan NPC multiplex families","volume":"155","author":"Hsu","year":"2024","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.medj.2025.100925_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14235780","article-title":"Functional Implications of Epstein-Barr Virus Lytic Genes in Carcinogenesis","volume":"14","author":"Yap","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.medj.2025.100925_bib68","first-page":"1188","article-title":"Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma","volume":"59","author":"Lo","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2025.100925_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms8121875","article-title":"Epstein-Barr Virus Reactivation-Induced Immunoglobulin Production: Significance on Autoimmunity","volume":"8","author":"Nagata","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.medj.2025.100925_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002904","article-title":"The ESCRT machinery is recruited by the viral BFRF1 protein to the nucleus-associated membrane for the maturation of Epstein-Barr Virus","volume":"8","author":"Lee","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.medj.2025.100925_bib71","doi-asserted-by":"crossref","first-page":"5078","DOI":"10.1128\/JVI.80.10.5078-5081.2006","article-title":"The Epstein-Barr virus BMRF1 gene is essential for lytic virus replication","volume":"80","author":"Neuhierl","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.medj.2025.100925_bib72","doi-asserted-by":"crossref","first-page":"6482","DOI":"10.1128\/JVI.03428-12","article-title":"Nuclear transport of Epstein-Barr virus DNA polymerase is dependent on the BMRF1 polymerase processivity factor and molecular chaperone Hsp90","volume":"87","author":"Kawashima","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.medj.2025.100925_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.513383","article-title":"Epstein-Barr Virus Early Protein BFRF1 Suppresses IFN-beta Activity by Inhibiting the Activation of IRF3","volume":"11","author":"Wang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.medj.2025.100925_bib74","doi-asserted-by":"crossref","first-page":"7899","DOI":"10.1128\/JVI.79.12.7899-7904.2005","article-title":"Epstein-Barr virus BZLF1 protein binds to mitotic chromosomes","volume":"79","author":"Adamson","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.medj.2025.100925_bib75","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1099\/vir.0.009571-0","article-title":"Epstein-Barr virus BDLF2-BMRF2 complex affects cellular morphology","volume":"90","author":"Loesing","year":"2009","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.medj.2025.100925_bib76","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1056\/NEJM198511143132002","article-title":"Recurrent sinopulmonary infection and impaired antibody response to bacterial capsular polysaccharide antigen in children with selective IgG-subclass deficiency","volume":"313","author":"Umetsu","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2025.100925_bib77","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2249.1995.tb03602.x","article-title":"Severity of infections in IgA deficiency: correlation with decreased serum antibodies to pneumococcal polysaccharides and decreased serum IgG2 and\/or IgG4","volume":"100","author":"French","year":"1995","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.medj.2025.100925_bib78","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1089\/088922201753197105","article-title":"HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression","volume":"17","author":"Ngo-Giang-Huong","year":"2001","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.medj.2025.100925_bib79","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1442-200x.2000.01175.x","article-title":"Analysis of IgG subclasses in chronic active Epstein-Barr virus infection","volume":"42","author":"Wakiguchi","year":"2000","journal-title":"Pediatr. Int."},{"key":"10.1016\/j.medj.2025.100925_bib80","doi-asserted-by":"crossref","first-page":"656","DOI":"10.4049\/jimmunol.1601574","article-title":"Antibody-Dependent NK Cell Activation Differentially Targets EBV-Infected Cells in Lytic Cycle and Bystander B Lymphocytes Bound to Viral Antigen-Containing Particles","volume":"199","author":"Lopez-Montanes","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.medj.2025.100925_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/cells10092458","article-title":"Radiotherapy Combined with PD-1 Inhibition Increases NK Cell Cytotoxicity towards Nasopharyngeal Carcinoma Cells","volume":"10","author":"Makowska","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.medj.2025.100925_bib82","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16071312","article-title":"The Role of Natural Killer Cells in the Tumor Immune Microenvironment of EBV-Associated Nasopharyngeal Carcinoma","volume":"16","author":"Li","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.medj.2025.100925_bib83","doi-asserted-by":"crossref","DOI":"10.3390\/v13020300","article-title":"The Role of NK Cells in EBV Infection and EBV-Associated NPC","volume":"13","author":"Png","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.medj.2025.100925_bib84","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061914","article-title":"The Role of NK Cells in EBV Infection and Related Diseases: Current Understanding and Hints for Novel Therapies","volume":"15","author":"Desimio","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.medj.2025.100925_bib85","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1200\/JCO.22.01979","article-title":"Performance and Operational Feasibility of Epstein-Barr Virus-Based Screening for Detection of Nasopharyngeal Carcinoma: Direct Comparison of Two Alternative Approaches","volume":"41","author":"Lou","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2025.100925_bib86","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae464","article-title":"Association Between Antibodies That Bind Epstein-Barr Virus (EBV) gp350 and gH\/gL and Shedding of EBV in Saliva From Nasopharyngeal Carcinoma Multiplex Family Members in Taiwan","volume":"11","author":"Liu","year":"2024","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.medj.2025.100925_bib87","article-title":"A large-scale population-based study reveals that gp42-IgG antibody is protective against EBV-associated nasopharyngeal carcinoma","volume":"135","author":"Kong","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.medj.2025.100925_bib88","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0587","article-title":"Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti-Programmed Cell Death 1 Immunotherapy","volume":"5","author":"Xu","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.medj.2025.100925_bib89","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1097\/00006454-199008001-00004","article-title":"IgG subclass distribution of antibodies to bacterial and viral antigens","volume":"9","author":"Ferrante","year":"1990","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.medj.2025.100925_bib90","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.medj.2025.100925_bib91","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.it.2019.01.005","article-title":"Role of IgG3 in Infectious Diseases","volume":"40","author":"Damelang","year":"2019","journal-title":"Trends Immunol."},{"key":"10.1016\/j.medj.2025.100925_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.867918","article-title":"Four Decades of Prophylactic EBV Vaccine Research: A Systematic Review and Historical Perspective","volume":"13","author":"Escalante","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.medj.2025.100925_bib95","author":"Roy"},{"key":"10.1016\/j.medj.2025.100925_bib93","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1093\/jnci\/94.23.1780","article-title":"Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan","volume":"94","author":"Hildesheim","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.medj.2025.100925_bib94","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1002\/cncr.33799","article-title":"Cancer patterns in nasopharyngeal carcinoma multiplex families over 15 years","volume":"127","author":"Yu","year":"2021","journal-title":"Cancer"}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025003526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025003526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:20:49Z","timestamp":1773832849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634025003526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":95,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2666634025003526"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2025.100925","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epstein-Barr-virus-specific functional antibody signatures in the context of nasopharyngeal carcinoma development","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2025.100925","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100925"}}